You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 58 No. 7, July 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (45)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Panic Disorder
 •Psychopharmacology
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic

Early Coadministration of Clonazepam With Sertraline for Panic Disorder

Andrew W. Goddard, MD; Thomas Brouette, MD; Ahmad Almai, MD; Praveen Jetty, MD; Scott W. Woods, MD; Dennis Charney, MD

Arch Gen Psychiatry. 2001;58:681-686.

Background  There is debate about combining benzodiazepines with selective serotonin reuptake inhibitors in the acute treatment of panic disorder. Although this medication combination is widely used in clinical practice, there is no well-tested, optimal method of coadministering these medications for the treatment of panic disorder. The purpose of this study was to test the efficacy of early coadministration of clonazepam with sertraline in the treatment of panic disorder.

Methods  Fifty patients with panic disorder were randomized into a double-blind clinical trial. Patients received open-label sertraline for 12 weeks (target dose, 100 mg/d), and in addition were randomized to groups receiving either 0.5 mg of active clonazepam 3 times daily or placebo clonazepam for the first 4 weeks of the trial. The clonazepam dose was then tapered during 3 weeks and discontinued.

Results  Thirty-four (68%) of 50 patients completed the trial. Drop-out rates were similar in the sertraline/placebo vs the sertraline/clonazepam group (38% vs 25%) (P = .5). An intent-to-treat analysis (on last observation carried forward data) revealed a much greater proportion of responders in the sertraline/clonazepam compared with the sertraline/placebo group at the end of week 1 of the trial (41% vs 4%) (P = .003). There was also a significant between-group difference at the end of week 3 with 14 (63%) of 22 of the sertraline/clonazepam group responding to treatment vs 8 (32%) of 25 of the sertraline/placebo group (P = .05). This difference was not observed at other times during the trial.

Conclusion  These data indicate that rapid stabilization of panic symptoms can be safely achieved with a sertraline/clonazepam combination, supporting the clinical utility of this type of regimen for facilitating early improvement of panic symptoms relative to sertraline alone.


From the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn (Drs Goddard, Brouette, Almai, Jetty, and Woods); and the National Institutes of Mental Health, Bethesda, Md (Dr Charney). Dr Brouette is currently in private practice in Danville, Pa; Dr Jetty is currently in private practice in Birmingham, Ala.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.